Products Categories
| CAS No.: | 12650-69-0 |
|---|---|
| Name: | Mupirocin |
| Article Data: | 4 |
| Molecular Structure: | |
|
|
|
| Formula: | C26H44O9 |
| Molecular Weight: | 500.63 |
| Synonyms: | 5,9-Anhydro-2,3,4,8-tetradeoxy-8-[[3-(2-hydroxy-1-methylpropyl)oxiranyl]methyl]-3-methyl-[2E,8[2S,3S(1S,2S)]]-L-talonon-2-enonic acid 8-carboxyoctyl ester;Mupirocinum;Pseudomonic acid;Pseudomonic acid A;UNII-D0GX863OA5; |
| EINECS: | 231-791-2 |
| Density: | 1.183 g/cm3 |
| Melting Point: | 77-78 ºC |
| Boiling Point: | 672.3 ºC at 760 mmHg |
| Flash Point: | 216.5 ºC |
| Solubility: | soluble in water: 12 mg/mL |
| Appearance: | white crystalline solid |
| PSA: | 146.05000 |
| LogP: | 2.59250 |
- 144851-82-1METHYL2-AMINO-3-FLUOROBENZOATE
- 483366-12-7(2S,4R)-1-Boc-2-cyano-4-hydroxypyrrolidine
- 173606-50-3BOC-10-AMINODECANOIC ACID
- 361456-36-2METHYL (R)-(+)-ISOCYANATO-3-PHENYLPROPI&
- 5156-58-1N-(1-Benzyl-4-pipperidinyl)-N-phenylpropanamide HCl
- 81281-59-67-Benzylideneaminotheophylline
- 50288-62-5threo-Phenyl-2-piperidyl acetamide
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 47087-37-6Z-D-Glu-OMe
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 33089-61-1Amitraz
- 87413-09-0Dess-Martin periodinane
- 2491-38-5Ethanone,2-bromo-1-(4-hydroxyphenyl)-
- 64-75-52-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,hydrochloride (1:1), (4S,4aS,5aS,6S,12aS)-
- 870-24-62-Chloroethylamine hydrochloride
- 506-59-2Methanamine,N-methyl-, hydrochloride (1:1)
- 79-19-6N-Aminothiourea
- 134-85-04-Chlorobenzophenone
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Specification
Mupirocin is one kind of white crystalline solid. The IUPAC name of Mupirocin is 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl]oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid. Besides, Mupirocin belongs to active pharmaceutical ingredients; intermediates & fine chemicals; pharmaceuticals. It is an antibiotic originally isolated from Pseudomonas fluorescens NCIMB 10586, developed by Beecham. In addition, the Classification Code of it is Anti-Bacterial Agents; Anti-Infective Agents; Antibacterial [topical]; Drug / Therapeutic Agent; Enzyme Inhibitors; Natural Product; Protein Synthesis Inhibitors. The water solubility of Mupirocin is 2.65e-02 g/l. In other words, it can soluble in water which is 12 mg/mL.
Physical properties about Mupirocin are: (1)ACD/LogP: 3.443; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): 2.64; (4)ACD/LogD (pH 7.4): 0.85; (5)ACD/BCF (pH 5.5): 38.70; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 282.50; (8)ACD/KOC (pH 7.4): 4.53; (9)#H bond acceptors: 9; (10)#H bond donors: 4; (11)#Freely Rotating Bonds: 20; (12)Index of Refraction: 1.524; (13)Molar Refractivity: 129.517 cm3; (14)Molar Volume: 423.051 cm3; (15)Polarizability: 51.344 10-24cm3; (16)Surface Tension: 49.0620002746582 dyne/cm; (17)Density: 1.183 g/cm3; (18)Flash Point: 216.524 °C; (19)Enthalpy of Vaporization: 113.012 kJ/mol; (20)Boiling Point: 672.313 °C at 760 mmHg
Preparation of Mupirocin: Mupirocin is obtained by the Pseudomonas fluorescens which produces a class of substances, including Pseudomonas acid A, B, C, D. Mupirocin is one of the major metabolites Pseudomonas acid A.
Uses of Mupirocin: Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations. It is used topically and is effective against Gram-positive bacteria, including MRSA. treatment for bacterial skin infections. Mupirocin is a topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.
You can still convert the following datas into molecular structure:
(1)InChI=1S/C26H44O9/c1-16(13-23(30)33-11-9-7-5-4-6-8-10-22(28)29)12-20-25(32)24(31)19(15-34-20)14-21-26(35-21)17(2)18(3)27/h13,17-21,24-27,31-32H,4-12,14-15H2,1-3H3,(H,28,29)/b16-13+/t17-,18-,19-,20-,21-,24+,25-,26-/m0/s1;
(2)InChIKey=MINDHVHHQZYEEK-HBBNESRFSA-N;
(3)SmilesC1[C@@H]([C@H]([C@H]([C@@H](O1)C\C(=C\C(OCCCCCCCCC(O)=O)=O)C)O)O)C[C@H]1[C@@H](O1)[C@H]([C@H](C)O)C;
The following are the toxicity data which has been tested.
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | intravenous | 1638mg/kg (1638mg/kg) | United States Patent Document. Vol. #4206224, | |
| mouse | LD50 | oral | 5gm/kg (5000mg/kg) | United States Patent Document. Vol. #4206224, | |
| mouse | LD50 | subcutaneous | 4gm/kg (4000mg/kg) | United States Patent Document. Vol. #4206224, | |
| rat | LD50 | intravenous | 1310mg/kg (1310mg/kg) | United States Patent Document. Vol. #4206224, | |
| rat | LD50 | oral | 5gm/kg (5000mg/kg) | United States Patent Document. Vol. #4206224, | |
| rat | LD50 | subcutaneous | 5gm/kg (5000mg/kg) | United States Patent Document. Vol. #4206224, |